MARKET

ALNA

ALNA

Allena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
-0.080
-5.76%
After Hours: 1.340 +0.03 +2.29% 17:58 10/26 EDT
OPEN
1.380
PREV CLOSE
1.390
HIGH
1.390
LOW
1.300
VOLUME
401.25K
TURNOVER
--
52 WEEK HIGH
6.30
52 WEEK LOW
0.5250
MARKET CAP
49.94M
P/E (TTM)
-0.8108
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Zacks · 5d ago
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Zacks · 10/14 16:32
What Makes Allena Pharmaceuticals, Inc. (ALNA) a New Buy Stock
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 10/06 16:00
Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors
NEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced
GlobeNewswire · 10/05 12:00
GNW, SELB among premarket losers
Zosano Pharma (ZSAN) -53% after FDA discipline review letter for Qtrypta.Selecta Biosciences (SELB) -44% after SEL-212 misses primary endpoint in mid-stage gout study.LogicBio Therapeutics (LOGC) -26% on launch of equity offering.ChinaNet Online Holdings (CNET) -22%.CynergisTek (CTEK)
Seekingalpha · 10/01 12:16
OAS, OMP, CTIC and NNDM among midday movers
Gainers: Iterum Therapeutics (ITRM) +146%.CTI BioPharma (CTIC) +110%.CynergisTek (CTEK) +69%.Nano Dimension (NNDM) +38%.Wanda Sports Group (WSG) +28%.Genetron (GTH) +24%.Allena Pharmaceuticals (ALNA) +20%.Sky Solar (SKYS) +19%.RAPT Therapeutics (RAPT) +19%.Limbach Holdings (LMB) +16%.Losers: Aptorum
Seekingalpha · 09/30 16:43
CTI BioPharma, Genetron Holdings leads healthcare gainers, Aptorum Group, Adial Pharmaceuticals among major losers
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon GloboCare (AVCO) -15%, Galectin Therapeutics (GALT) -15%, Windtree Therapeutics (WINT) -13%.
Seekingalpha · 09/30 15:00
Why Allena Pharmaceuticals Is Trading Higher Today
Allena Pharmaceuticals (NASDAQ: ALNA) shares are trading higher on Wednesday after the company announced a $25 million strategic convertible debt financing agreement with Pontifax Ventures.
Benzinga · 09/30 14:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALNA. Analyze the recent business situations of Allena through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALNA stock price target is 7.83 with a high estimate of 18.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 15.33M
% Owned: 40.23%
Shares Outstanding: 38.12M
TypeInstitutionsShares
Increased
7
827.97K
New
13
-1.64M
Decreased
9
305.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Co-Founder/Director
Alexey Margolin
President/Chief Executive Officer/Director
Louis Brenner
Chief Financial Officer
Edward Wholihan
Director
Bob Tepper
Director
Ann Miller
Independent Director
Robert Alexander
Independent Director
Allene Diaz
Independent Director
Andrew Hack
Independent Director
Gino Santini
Independent Director
James Topper
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALNA
Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. It is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its pipeline includes reloxaliase and ALLN-346. Reloxaliase is an oral enzyme therapeutic that is being developed for the treatment of hyperoxaluria. ALLN-346 is designed to be an orally-administered non-absorbed urate-degrading enzyme. ALLN-346 is being developed to degrade urate in the gastrointestinal (GI) tract.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Allena Pharmaceuticals Inc stock information, including NASDAQ:ALNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNA stock methods without spending real money on the virtual paper trading platform.